NCT03415906撤回2 期
Influences of Angiotensin-neprilysin Inhibition With Sacubitril/Valsartan (ENTRESTO®) on Centrally Generated Sympathetic Activity in Heart Failure Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- MSNA burst frequency [bursts/min]
研究概览
简要总结
The autonomic nervous system plays an important role in controlling the circulation. Increased sympathetic activity has detrimental effects in patients with heart failure.
The purpose of this study is to test the hypothesis that combined angiotensin receptor + neprilysin inhibition results in lower sympathetic activity than angiotensin receptor inhibition alone.
详细描述
Thirty-five heart-failure patients will be included in a prospective, monocentric, active-controlled, double-blind, cross-over study with randomized sequence of treatments sacubitril+valsartan or valsartan alone. After open-label dose finding and washout patients will be randomly assigned to the treatment sequence [sac+val --> val] or [val --> sac+val]. The two treatment periods of 4 weeks duration will be separated by 2 weeks of washout. At the end of both treatments the state of the cardiovascular system and its control will be measured.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
盲法说明
double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Women or men at the age ≥ 18 years, ≤ 80 years and able to give written informed consent
- •Heart failure NYHA class II-III
- •Ejection fraction of 40 % or less
- •Stable dose of an ACE inhibitor or ARB over the last 4 weeks (A 2-day ACE inhibitor washout is scheduled before run-in; see Figure 3 on page 29.)
- •Stable dose of a beta-blocker over the last 4 weeks unless contraindicated or not tolerated
- •Patient has to be in sinus rhythm
- •Patients capable of understanding the investigational nature, potential risks and benefits of the clinical trial
- •Women without childbearing potential defined by:
- •at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
- •hysterectomy or uterine agenesis or
- •≥ 50 years and in postmenopausal state ≥ 1 year or
- •< 50 years and in postmenopausal state ≥ 1 year with urine FSH > 40 IU/l and urine estrogen < 30 ng/l or a negative estrogen test OR
- •Women of childbearing potential with a negative urine ß-HCG pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 7 days following the last administration of study medication:
- •correct use of at least an acceptable effective contraceptive measure. The following are deemed acceptable in this study: hormonal contraceptives (combined oral contraceptives and estrogen-free pills with desogestrel, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUS))
- •true abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)
- •sexual relationship only with female partners and/or sterile male partners OR Male
- •Signed written informed consent and willingness to comply with treatment and follow- up procedures.
排除标准
- •History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACE inhibitors (ACE-Is), ARBs, or neprilysin inhibitors, as well as known or suspected contraindications to the study drugs
- •History of angioedema
- •Recent acute decompensated heart failure within 2 months before screening
- •Symptomatic hypotension and/or office systolic BP <110 mmHg at screening measured according to the recommendations of the European Society of Hypertension
- •Combined intake of an ACE inhibitor and ARB over the last 4 weeks
- •Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²
- •Concomitant medication with Aliskiren in patients with Diabetes or patients with eGFR < 60 mL/min/1.73 m²
- •Serum potassium >5.2 mmol/L at Visit 1 (screening)
- •Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid, or other major cardiovascular surgery, PCI, or carotid angioplasty within the 3 months before screening
- •History of heart transplant or on a transplant list or with LV assistance device
- •History of severe pulmonary disease
- •Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months prior to Visit 1
- •Presence of hemodynamically significant mitral and/or aortic valve disease/ left ventricular outflow tract obstruction, except mitral regurgitation secondary to LV dilatation
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs
- •Evidence of hepatic disease as determined by any one of the following: aspartate aminotransferase or alanine aminotransferase values exceeding 2× upper limit of normal at Visit 1, history of hepatic encephalopathy, history of esophageal varices, or history of porto-caval shunt
- •Contraindications precluding microneurography measurements, such as relevant peripheral neuropathy as judged by the investigator
- •Pregnancy or lactation period
- •Current participation in any other clinical trial or participation in another clinical trial within 30 days before screening
- •Known or suspected hypersensitivity to any of the active substances or any excipients of the investigational medicinal products
- •Vulnerable subjects (i.e. persons under any administrative or legal supervision or persons kept in detention)
研究组 & 干预措施
sacubitril+valsartan
Experimental
Combined angiotensin receptor and neprilysin inhibition
干预措施: sacubitril+valsartan (Combination Product)
valsartan
Active Comparator
Angiotensin receptor inhibition alone
干预措施: valsartan (Drug)
结局指标
主要结局
MSNA burst frequency [bursts/min]
时间窗: For 5 minutes at the end of both treatments
Bursts of vasoconstrictor sympathetic nerve activity directed to skeletal muscle (muscle sympathetic nerve activity, MSNA) per minute
次要结局
- PVN activity [unitless](For 20 minutes at the end of both treatments)
- MSNA burst area [au/min](For 5 minutes at the end of both treatments)
- Cardiac baroreflex gain [ms/mmHg](For 5 minutes at the end of both treatments)
- DBP [mmHg](For 5 minutes at the end of both treatments)
- NTS activity [unitless](For 20 minutes at the end of both treatments)
- MSNA burst incidence [bursts/100 heartbeats](For 5 minutes at the end of both treatments)
- Sympathetic baroreflex gain [bursts/mmHg](For 5 minutes at the end of both treatments)
- NE [nM](After 20 minutes of supine rest at the end of both treatments)
- Sympathetic excitability [bursts](For 3 minutes at the end of both treatments)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
The effect of autonomic nerve activity and cardiovascular system on Mozart's musichealthy adultsJPRN-UMIN000028247Tohoku University Graduate School of Medicine30
进行中（未招募）
1 期
Influences of Sacubitril/Valsartan (ENTRESTO®) on centrally generated sympathetic activity in heart failure patientsChronic heart failure with reduced left ventricular ejection fraction (NYHA II-III)MedDRA version: 20.0Level: LLTClassification code 10078289Term: Heart failure with reduced ejection fractionSystem Organ Class: 100000004849EUCTR2017-000394-36-DEHannover Medical School35
已完成
不适用
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic HypotensionPure Autonomic FailureParkinson's DiseaseOrthostatic HypotensionMultiple System AtrophyNCT01316666Vanderbilt University Medical Center50
Unknown
不适用
Influence of the Autonomic Nervous System in Response to Exercise in Hypertensive IndividualsAutonomic Nervous SystemHypertensionNCT04371757Instituto de Cardiologia do Rio Grande do Sul39
已完成
不适用
Renal Sympathetic Denervation Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot StudyHypertensive Heart DiseaseAutonomic ImbalanceAtrial FibrillationHypertensionNCT01990911Pace Clinic80